An important correlation between enhanced insulin sensitivity and both plasma ApoC-III and TG suppression was also reported through the effects of the antisense APOC3 inhibitor — volanesorsen (ISIS 304801) — on TG levels and insulin resistance in patients with type 2 diabetes [61]. Here, APOC3 is linked to type 2 diabetes mellitus.